Icon Plc
ICLR
Get informed when a big investor buys or sells
+ FollowEarnings Call Q3 2024
October 24, 2024 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
17.2% upsideUndervalued by 17.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.42 Billion |
|---|---|
| Enterprise Value | $14.90 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.92 |
| Beta | 1.23 |
| Outstanding Shares | 78,423,675 |
Return
| Return on Equity | 2.49% |
|---|---|
| Return on Assets | 1.41% |
| Return on Invested Capital | 3.37% |
Valuation & Multiples
| P/E Ratio | 47.15 |
|---|---|
| PEG | -33.12 |
| Price to Sales | 1.46 |
| Price to Book Ratio | 1.31 |
| Enterprise Value to Revenue | 1.81 |
| Enterprise Value to EBIT | 33.81 |
| Enterprise Value to Net Income | 64 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6138▲ 20.80% |
|---|---|
| Total Calls | 327,800▲ 41.35% |
| Total Puts | 201,200▲ 113.82% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 100.97%▲ 0.99% |
|---|---|
| Total Invested | $8.74B▼ 38.02% |
| Investors Holding | 438▼ 85.00% |
ESG Score
No data
About Icon Plc
CEO: Stephen Cutler Relevant Senate Committees
As the expert body providing official revenue estimates for all tax bills, its technical expertise and reports directly influence corporate tax structures and capital investment credits, critically affecting Icon Plc's financial planning and operational costs.
This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy (e.g., R&D credits) and Medicare pricing directly impact the financial health and market potential of Icon Plc's pharmaceutical clients.
This committee allocates discretionary federal spending, and its subcommittees directly determine the precise funding for scientific research programs (e.g., NIH, CDC), which directly affects the volume and types of research projects Icon Plc conducts.
This committee directly regulates the FDA and NIH, which are central to drug approval processes and research funding, making it highly influential over the pharmaceutical and biotech sectors, directly impacting Icon Plc's business.
This committee's jurisdiction over intellectual property laws is critical for biotechnology and drug development, and its role in antitrust oversight can influence mergers in the pharma industry, impacting Icon Plc's client base and competitive landscape.
Members receive classified briefings on global threats, including potential biological threats or health crises, which can directly drive R&D funding and priorities in the biotech sector, creating high informational asymmetry relevant to Icon Plc.